Resistence to Diet-Induced Obesity in Mice with Synthetic Glyoxylate Shunt

Jason T. Dean,1 Linh Tran,1 Simon Beaven,2,3 Peter Tontonoz,3 Karen Reue,4 Katrina M. Dipple,4,5,* and James C. Liao1,*

1Department of Chemical and Biomolecular Engineering
2Department of Medicine, Division of Digestive Diseases
3Howard Hughes Medical Institute
4Department of Human Genetics
5Department of Pediatrics
University of California, Los Angeles, CA 90095, USA
*Correspondence: kdipple@mednet.ucla.edu (K.M.D.), liaoj@ucla.edu (J.C.L.)
DOI 10.1016/j.cmet.2009.04.008

SUMMARY

Given the success in engineering synthetic phenotypes in microbes and mammalian cells, constructing non-native pathways in mammals has become increasingly attractive for understanding and identifying potential targets for treating metabolic disorders. Here, we introduced the glyoxylate shunt into mouse liver to investigate mammalian fatty acid metabolism. Mice expressing the shunt showed resistance to diet-induced obesity on a high-fat diet despite similar food consumption. This was accompanied by a decrease in total fat mass, circulating leptin levels, plasma triglyceride concentration, and a signaling metabolite in liver, malonyl-CoA, that inhibits fatty acid degradation. Contrary to plants and bacteria, in which the glyoxylate shunt prevents the complete oxidation of fatty acids, this pathway when introduced in mice increases fatty acid oxidation such that resistance to diet-induced obesity develops. This work suggests that using non-native pathways in higher organisms to explore and modulate metabolism may be a useful approach.

INTRODUCTION

The obesity epidemic is widespread in developed countries and is associated with the constellation of clinical problems known as the metabolic syndrome: insulin resistance, diabetes, cardiovascular disease, dyslipidemia, and fatty liver (Kahn et al., 2006; Van Gaal et al., 2006). Elevated levels of plasma free fatty acids are a risk factor for the development of type 2 diabetes (Paolisso et al., 1995) and are a biochemical hallmark of obesity. Fatty acids are used as an energy source in skeletal muscle and liver, and their use is tightly controlled by several factors including availability in the diet, de novo biosynthesis, glucose levels, and gluconeogenesis. Fatty acid and triglyceride biosynthesis is associated with high glucose concentrations and glycolytic rates, while fatty acid degradation generally occurs during periods of glucose starvation. Regulation of fatty acid biosynthesis and degradation ensures that glucose is oxidized preferentially before fatty acids in hepatocytes.

Under normal circumstances the liver stores very little lipid because hepatic lipogenesis is balanced with fatty acid degradation. Fatty acid biosynthesis begins with transport of citrate from the mitochondria to the cytosol where it is converted to oxaloacetate (OAA) and acetyl-CoA by citrate lyase (ACLY). The carboxylation of acetyl-CoA to malonyl-CoA by acetyl-CoA carboxylase (ACC) represents the first committed step in fatty acid biosynthesis. Hepatic fatty acids have two fates. They may be incorporated into triglycerides, which are packaged into very low-density lipoproteins and secreted into the blood to deliver lipids to other tissues. Alternatively, fatty acids are degraded via β-oxidation to generate reducing power and energy. Hepatic fatty acid degradation is regulated by the cytosolic metabolites citrate and malonyl-CoA. The former is an allosteric activator of ACC (Saha et al., 1999), and the latter is a potent inhibitor of carnitine palmitoyltransferase-1a (CPT1A) (McGarry and Brown, 1997), which mediates the transport of fatty acids into mitochondria for β-oxidation. High rates of fatty acid β-oxidation are linked to a decrease in malonyl-CoA levels and an increase in AMP-activated protein kinase (AMPK)-mediated ACC covalent inactivation (Kudo et al., 1995). The product of β-oxidation, acetyl-CoA, enters the TCA cycle.

Whereas adipose tissue is specialized to store lipids, excess triglyceride storage in the liver is a pathologic condition. In obesity, for example, the delivery of fatty acids liberated from adipocytes to the liver may outpace the capacity of hepatocytes for fatty acid oxidation, leading to triglyceride accumulation. This, in turn, promotes the development of nonalcoholic fatty liver disease, which is the most common cause of liver disease and occurs in 20%–40% of obese subjects (Brown and Horton, 2004; Farrell and Larter, 2006; Torres and Harrison, 2008; Youssef and McCullough, 2002). This suggests that increased hepatic fatty acid oxidation may have a favorable effect on comorbidities associated with obesity.

In this study, we exploit a metabolic pathway that is present in plants and bacteria, but not normally found in mammals, to perturb the balance of energy homeostasis and attempt to gain further insight into fatty acid oxidation in the liver. Since mammals do not have this shunt, its effect on liver metabolism cannot be predicted. In fact, opposite possibilities exist depending on the local context and cellular regulation. Remarkably, we found that human hepatocytes expressing the glyoxylate shunt have increased fatty acid oxidation, and mice expressing this shunt in the liver were resistant to diet-induced obesity. These...
effects were attributed to the decreased malonyl-CoA level and an additional oxidation pathway formed through the shunt and cytosolic malic enzyme (ME1) and phosphoenolpyruvate carboxykinase (PEPCK). Therefore, we demonstrate the potential benefit of using a non-native pathway to deliver a synthetic phenotype and identify potential targets for therapy.

**RESULTS**

**Possible Outcomes of Hepatic Glyoxylate Shunt Expression**

The glyoxylate shunt, isocitrate lyase (aceA) and malate synthase (aceB), is a two-enzyme pathway that allows the cell to conserve carbon by bypassing the oxidative CO2-producing reactions of the TCA cycle. This carbon conservation allows bacteria and plants to use fatty acids as a gluconeogenic substrate and avoid the complete oxidation of fatty acids to CO2. Regulation in plants and bacteria ensures that glyoxylate shunt expression is repressed in the presence of glucose and activated during growth on fatty acids.

Since mammals do not have the glyoxylate shunt, the result of its activity on mammalian energy metabolism is unknown. We hypothesized at least three possible net outcomes of the conservation of carbon metabolites that would occur by activating this pathway (Figure 1): (1) four-carbon gluconeogenic substrates would be generated and used for gluconeogenesis, similar to plants and bacteria; (2) the four-carbon TCA cycle intermediated would be converted to citrate, which would be exported from mitochondria and converted into malonyl-CoA, which reduces fatty acid degradation; or (3) the conserved carbon metabolite would be oxidized through either cytosolic malic enzyme (ME1) or phosphoenolpyruvate carboxykinase (PEPCK) and pyruvate dehydrogenase complex (additional details in the Supplemental Data available online). The first two possibilities are direct consequences of carbon saving due to bypassing the decarboxylation part of the TCA cycle. Thus, these two possibilities lead to either no change or decreased fatty acid oxidation and a possible increase in cell mass. On the other hand, the third possibility essentially provides an additional pathway for complete fatty acid oxidation to CO2. This route avoids malonyl-CoA build up and provides a favorable regulatory state for fatty acid oxidation. Among these possibilities, the cellular regulation in mammals will ultimately determine the outcome of this non-natural perturbation.
HepG2 Hepatocytes Expressing the Glyoxylate Shunt Have Increased Fatty Acid Degradation

To investigate these possibilities, we first constructed a stably transfected human HepG2 hepatocyte cell line constitutively expressing the glyoxylate shunt genes, aceA and aceB, from *E. coli* (designated ACE) (Figures 2A–2C). We found that ACE cells exhibited higher palmitate uptake rates than WT cells, and this phenotype persisted across a broad range of physiological fatty acid levels up to 1 mM palmitate (Figure 2D). Here WT refers to the HepG2 cell line stably transfected with an empty vector pBudCE4.1. A stable cell line expressing lacZ was also generated and found to have the same palmitate uptake rate as the WT cell line (data not shown). This phenotype was also demonstrated using a fluorescence-based uptake assay (Liao et al., 2005) employing fluorescently labeled dodecanoic acid bound to bovine plasma albumin (Figure 2E). Interestingly, palmitate taken up by ACE cells is not used for gluconeogenesis, as evidenced by the lack of 13C-labeled glucose generated from [U-13C] palmitate (Figure 2F), even though gluconeogenesis was functional in ACE cells (Figures 2F and S1). Rather, ACE cells were found to oxidize more than twice as much [U-13C] palmitate to 14CO2 than WT (Figure 2G). Taken together, these results demonstrate that ACE cells have increased overall fatty acid oxidation compared to WT cells. In addition, we found that ACE cells consumed less glucose (Figure 2H) and produced less lactate (Figure S2) than WT cells over a range of palmitate concentrations. In the absence of palmitate, ACE and WT cells consumed identical amounts of glucose (Figure 2H).

ME1 Expression Is Necessary for ACE Phenotype

The glyoxylate shunt may create an additional cycle for oxidizing acetyl-CoA (Figure 1) through either ME1 (Liao et al., 1996) or PEPCCK, and our results suggest that cells may use the shunt in this manner to increase fatty acid degradation in the presence of glucose. Since the cell culture metabolic studies were performed in high-glucose media, we expect ME1, a lipogenic enzyme (Stefos et al., 2009), to be the predominant pathway for recycling TCA intermediates to pyruvate and allowing for complete oxidation of fatty acids. According to this hypothesis, the flux through ME1 is necessary for the increased fatty acid degradation in ACE cells. To test this hypothesis, we used siRNA to knockdown ME1 in both ACE and WT cells. Knockdown of ME1 resulted in ACE and WT cells consuming identical amounts of palmitate (Figures 2I and S3), abolishing the increased fatty acid degradation observed in ACE cells and supporting our conclusion that ME1 and the glyoxylate shunt created an additional pathway for acetyl-CoA oxidation.

ACE Cells Exhibit Posttranslational and Transcriptional Changes Consistent with Metabolic Phenotype

We also investigated the effect of the glyoxylate shunt on signal transduction pathways. In particular, phosphorylated AMPK, designated pAMPK Thr172, was significantly increased in ACE cells compared to WT (Figure 3A), despite similar AMPK protein (Figure 3A) and mRNA levels. Activated phosphorylated AMPK can inactivate ACC by phosphorylation on serine 79 (Park et al., 2002), leading to decreased malonyl-CoA production and decreased CPT1A inhibition. Examination of the levels of active and inactive (designated pACC Ser79) forms of ACC revealed that the active form was lower in ACE than in WT cells and the inactive form was higher in ACE cells (Figure 3A). These results suggest that the association between the phosphorylated levels of AMPK and ACC play a role in allowing ACE cells to metabolize fatty acid at a higher rate than WT. Taken together, these signal transduction responses are consistent with the observed ACE metabolic phenotype.

In addition to signal transduction and metabolic adaptations, microarray analysis showed that ACE cells had a gene-expression profile that was consistent with the observed metabolic phenotype (Figure 3B and Tables S1–S5). In particular, CTP1A, which facilitates the transport of fatty acids from the cytoplasm to the mitochondria, and fatty acid-CoA ligase (FACL3), an enzyme involved in β-oxidation, were found to have a higher expression level in ACE cells compared to WT. In addition, genes involved in TG production were found to have markedly lower expression levels in ACE cells compared to WT. Consistent with the decreased glucose consumption observed, ACE cells showed lower expression of genes from glycolysis. Furthermore, microarray analysis showed that uncoupling protein 2 (UCP2) mRNA levels were higher in ACE cells than WT (2.38 ± 0.52) (Tables S1–S5).

Mice Expressing the Glyoxylate Shunt Resist Diet-Induced Obesity

To determine the effect of liver-specific glyoxylate shunt expression on whole-animal metabolism, we injected male and female C57BL/6 mice into the tail vein with vectors containing either aceA and aceB (designated ACE) or lacZ under control of a liver-specific promoter and monitored them for 6 weeks (Experiment 1, Figure S4). Male and female mice were injected at 20 g (6–7 weeks of age) and placed on a standard chow diet (LFD, 13.2% calories from fat, 4.07 kcal/g) or a high-fat diet (HFD, 60% calories from fat, 5.24 kcal/g) for 6 weeks. Plasma alanine aminotransferase (ALT) levels, a marker for hepatocellular damage, were normal for both male and female ACE and lacZ-injected mice (Figure S5). Body weight was measured weekly for 6 weeks. Four weeks postinjection, mice were fasted overnight and blood was drawn retro-orbitally. Six weeks postinjection body composition was analyzed by nuclear magnetic resonance (NMR), after which mice were sacrificed and tissues were collected.

Reverse-transcriptase PCR from liver, lung, and kidney shows that glyoxylate shunt expression was specific to liver (Figure 4A), active as determined by enzyme assay (Figure 4B), and maintained for the duration of diet experiments. We found that both male and female ACE mice gained less weight on a HFD than mice injected with lacZ (Figures 4C–4E and S6), and this resistance to diet-induced obesity was significant after 3 weeks. We found that female ACE mice weighed 5.2 g less than lacZ-injected mice after 6 weeks on a HFD (Figures 4C and 4D), and male ACE mice weighed 2.6 g less than the lacZ-injected mice (Figure 4E). Conversely, the glyoxylate shunt has little effect on mice fed a LFD. Female (Figure 4D) and male (Figure 4E) ACE mice were found to gain similar or slightly less weight over the course of 6 weeks on a LFD compared to the lacZ-injected mice.

ACE Mice Have Decreased Total Body Fat

We also found that glyoxylate shunt expression led to significant changes in body composition in female mice. Female ACE mice...
Figure 2. Human HepG2 Hepatocytes Expressing the Glyoxylate Shunt Have Increased Fatty Acid Degradation
(A) Reverse transcriptase PCR products from ACE cells (lanes 1 and 4) and WT cell lines (lanes 2 and 3) were run on a 1% agarose gel. The sizes of the ACEA (1.3 kb) and ACEB (1.6 kb) mRNA are shown (lanes 1 and 4 respectively).
(B) Western blot analysis of protein extracts from ACE (lanes 1 and 3) and WT (lanes 2 and 4) cells indicating the 61 kDa ACEA and the 48 kDa ACEB proteins.
(C) Enzyme assay shows that the glyoxylate shunt was active in ACE cells. Mean ± SEM.
(D) Fatty acid uptake rate over a range of palmitate concentrations for both ACE (closed squares) and WT (open squares). *p < 0.05 compared to corresponding WT control; mean ± SEM; n = 3–6.
(E) Fatty acid uptake assay using fluorescently labeled dodecanoic acid confirms that the ACE cells take up fatty acids more rapidly than WT. Image is representative of two experiments.
(F) Gluconeogenesis was assessed by measuring [U-13C] glycerol and [U-13C] palmitate incorporation into glucose. The glucose pentacetate derivative containing glucose carbons 2–6 was analyzed with GC-MS. ACE cells incorporate [U-13C] glycerol into glucose, as evidenced by the increased 13C enrichment in glucose.
(G) [U-14C] palmitate was used to measure palmitate oxidation to CO2. WT was used as a normalization basis. *p < 0.05 compared to corresponding WT control; mean ± SEM; n = 3.
(H) Glucose uptake over a range of palmitate concentrations for both ACE (closed squares) and WT (open squares). ACE cells consume less glucose than WT cells. *p < 0.05 compared to corresponding WT control. Mean ± SEM; n = 3–6.
(I) Palmitate uptake for ACE ME1 knockdown (ACE-ME1-KD) and WT ME1 knockdown (WT-ME1-KD). ME1 KD results in ACE and WT cells consuming identical amounts of palmitate. Mean ± SEM; n = 6.
were found to have 28% body fat and lacZ-injected mice 36% after 6 weeks on HFD (Figures 4F and 4G). In addition, fat mass was reduced in female ACE mice by more than 4 g, accounting for over 80% of the weight difference between ACE and lacZ-injected mice (Figure 4F). On LFD, female ACE mice were found to have 8% body fat and lacZ-injected mice 11% (Figures 4F and 4G) even though there was not a significant difference in body weight. Although male ACE mice gained less weight on both HFD and LFD than lacZ-injected mice, there was not a significant difference in body fat percentage (Figure 4G). However, male ACE mice on HFD gained significantly less fat mass than lacZ-injected mice (Figure 4F).

Female ACE Mice Accumulate Less Visceral Fat and Have Decreased Circulating Leptin Levels

Our results indicate that the glyoxylate shunt exerts a greater effect on female mice than male mice even though female and male mice displayed similar levels of aceA and aceB gene expression (Figure S7). This may be related to the inherent sexually dimorphic properties of fatty acid metabolism (Jalouli et al., 2003; Luxon and Weisiger, 1993; Sheorain et al., 1979) and may be partially attributed to hormonal differences. Because of the more dramatic phenotype seen in female mice on HFD, we chose to study this group in more detail. Female mice were injected at 7 weeks of age as described above and then placed on a HFD. Two weeks postinjection, mice were analyzed in metabolic cages to assess the effects of glyoxylate shunt expression on energy expenditure, respiratory exchange ratio, and activity. Six weeks after injection, blood and tissues were collected for analysis (Experiment 2, Figure S8).

Visceral fat, adipose tissue stored in the intra-abdominal area, is associated with type 2 diabetes and atherosclerosis (Tran et al., 2008). After dissection of the animals, we found significantly smaller visceral fat pads in female ACE mice (Figure 5A). We also found that a smaller percentage of body weight is attributed to visceral fat in female ACE mice compared to lacZ-injected mice (Figure 5B). Consistent with this result, female ACE mice had decreased circulating levels of the adipokine leptin (Figure 5C).

Female ACE Mice Have Decreased Liver Malonyl-CoA and ATP Levels

As demonstrated, the glyoxylate shunt may create an alternate cycle for acetyl-CoA oxidation (Figure 1). The key feature of this pathway is that it avoids malonyl-CoA production and is expected to increase fatty acid degradation. We found that female ACE mice had decreased liver malonyl-CoA levels compared to lacZ-injected mice on HFD (Figure 6A). This indicates that female ACE mice may resist diet-induced obesity in part due to decreased liver malonyl-CoA and therefore decreased CPT1a inhibition. On LFD, female ACE mice were found to have decreased liver malonyl-CoA, although the difference was not significant. The glyoxylate shunt bypasses isocitrate dehydrogenase, 2-oxoglutarate dehydrogenase, and succinyl-CoA ligase, enzymes producing reducing equivalents and ATP. We found decreased liver ATP levels (Figure 6B) in female ACE mice compared to lacZ-injected mice, indicating that the glyoxylate shunt functions to bypass the oxidative portion of the TCA cycle. This result may also explain the observed AMPK activation (Figure 3A) in our hepatocyte culture model.

Female ACE Mice Have Decreased Liver and Plasma Triglyceride Levels

Hepatic TG accumulation, often associated with insulin resistance (Yki-Jarvinen, 2005), was found to be slightly lower in

Figure 3. Posttranslational and Gene Expression Changes in ACE Cells Are Consistent with Increased Fatty Acid Degradation

(A) Western blot analysis of WT (left panel) and ACE (right panel) cell lines. ACE and WT cells were given DMEM supplemented with 300 μM palmitate, and protein was harvested at various time points over 24 hr. Blots are representative of two experiments.

(B) Metabolic networks related to glucose and fatty acid metabolism. Microarray analysis showing relative (fold change) gene-expression levels in the genes involved in glycolysis, fatty acid β-oxidation, and triglyceride synthesis from ACE and WT cell lines. Positive numbers indicated that the ACE cell line had higher expression levels than WT and are indicated by red arrows. Negative numbers indicate that the ACE cell line had lower expression levels and are indicated by green arrows. Data are represented as mean ± SEM; n = 2. Dashed green line represents allosteric regulation; malonyl-CoA inhibits CPT1a. Abbreviations are listed in Table S1. Key enzymes are shown in blue circles: malic enzyme (ME1), pyruvate dehydrogenase (PDH), pyruvate carboxylase (PC), acetyl-CoA carboxylase (ACC), and carnitine palmitoyltransferase-1a (CPT1A).
Figure 4. Mice Expressing the Glyoxylate Shunt in the Liver Resist Diet-Induced Obesity and accumulate Less Fat Mass on an HFD

(A) aceA and aceB were present exclusively in liver tissue as determined by reverse-transcriptase PCR at the end of diet experiments.

(B) The glyoxylate shunt was functional in ACE mice, as determined by enzyme assay. Mean ± SEM.

(C) Female ACE and lacZ-injected mice after 6 weeks on HFD. Female ACE mice gain less weight than lacZ-injected mice.

(D) Weight gain over 6 weeks for LFD and HFD for female mice. *p < 0.05 compared to corresponding lacZ-injected mouse on same diet; mean ± SEM; n = 4–6.

(E) Weight gain over 6 weeks for LFD and HFD for male mice. *p < 0.05 compared to corresponding lacZ-injected mouse on same diet; mean ± SEM; n = 4–6.

(F) Body composition as assessed at the conclusion of diet experiments using NMR. Female ACE mice have decreased total fat mass after 6 weeks on both LFD and HFD. *p < 0.05 for ACE fat mass compared to lacZ-injected mouse fat mass. Mean ± SEM; n = 4–6.

(G) Body fat percentage for ACE and lacZ-injected mice. Female ACE mice have decreased body fat percentage. *p < 0.05 compared to corresponding lacZ-injected mouse on same diet; mean ± SEM; n = 4–6.
female ACE mice as determined by liver TG content (Figure 6C). Analysis of plasma revealed that female mice expressing the glyoxylate shunt have different metabolite profiles than those expressing lacZ (Figure 6D). Female ACE mice were found to have lower triglyceride plasma concentrations than lacZ-injected mice after 4 weeks on a HFD (Figure 6D). Female ACE mice on a HFD were also found to have decreased plasma total cholesterol concentrations than lacZ-injected mice (Figure 6D). Since acetyl-CoA is the precursor for hepatic cholesterol biosynthesis, the glyoxylate shunt may lower cholesterol levels by providing an alternate acetyl-CoA consuming pathway. We did not find a difference in free fatty acid or glucose levels (Figure 6D).

Female ACE mice were found to have lower plasma concentrations of the ketone body 3-hydroxybutyrate (Figure 6E). Keto genesis is typically proportional to fatty acid oxidation (Beylot, 1996) and mitochondrial acetyl-CoA levels. ACE mice may have lower circulating ketone body levels despite increased hepatic fatty acid oxidation due to glyoxylate shunt consumption of acetyl-CoA, the ketone body precursor substrate. We found no difference in plasma insulin levels (Figure S9).

**Female ACE Mice Have Increased CPT1a and PEPCK Gene Expression**

We next examined the effect of glyoxylate shunt expression on mRNA levels of enzymes from the fatty acid degradation and gluconeogenic pathways. Female ACE mice were found to have increased expression of UCP2 and CPT1a (Figure 6F), congruous with our cell-culture microarray analysis. While these results indicate increased hepatic fatty acid oxidation in ACE mice, we found no difference in the mRNA levels of glucose-6-phosphatase (Figure 6F), an enzyme catalyzing the final step in gluconeogenesis. This result coupled with the finding that ACE and lacZ-injected mice have identical fasting plasma glucose concentrations (Figure 6D) further supports our conclusion that the glyoxylate shunt does not function as a gluconeogenic pathway in hepatocytes.

Female ACE mice were also found to have increased PEPCK mRNA levels (Figure 6F). This suggests that a cycle through PEPCK and the glyoxylate shunt for complete acetyl-CoA oxidation to CO₂ is functional in vivo (Figure 1). This is in contrast to our cell-culture model, where ME1 was implicated in a similar cycle (Figure 2I). A possible explanation for this difference is that mice were subjected to an overnight fast before tissue collection, a state that has been shown to increase PEPCK expression (Granner and Pilkis, 1990; Patsouris et al., 2004).

**Female ACE Mice Have Decreased Respiratory Exchange Ratio**

Respiratory exchange ratio (RER), a ratio of carbon dioxide production to oxygen consumption and an indicator of relative total body carbohydrate and fatty acid oxidation, was slightly lower in ACE mice during both the dark and light cycles as well as over the entire 24 hr period (Figure 7B) of analysis. An RER of 1.00 corresponds to “pure” carbohydrate oxidation (100% of total O₂ consumed by metabolism of carbohydrate, 0% from fat), while an RER of 0.70 represents “pure” fatty acid oxidation (100% of total O₂ consumed by metabolism of fat, 0% from carbohydrate). Thus, the decreased RER in ACE mice is indicative of increased total body fatty acid oxidation. This result may partially explain the decreased fat and hepatic TG accumulation in ACE mice (Figures 4F, 4G, and 6C). Female ACE mice also had a small increase in energy expenditure during the light cycle and over the entire 24 hr period (Figure 7C). ACE and lacZ-injected mice displayed similar oxygen consumption (Figure 7D) and ambulatory activity (Figure 7E).
DISCUSSION

Non-native pathways have been used to engineer novel biological functions and complex dynamics in both microbial (Atsumi et al., 2008; Elowitz and Leibler, 2000; Fung et al., 2005; Gardner et al., 2000; Kobayashi et al., 2004) and mammalian (Deans et al., 2007; Kramer et al., 2004; Tigges et al., 2009; Weber et al., 2006) systems. This strategy offers new opportunities for studying metabolic networks and, when applied to mammals, whole-body metabolism. To investigate fatty acid metabolism and identify potential targets for treating obesity, we introduced a non-native pathway, the glyoxylate shunt from *E. coli*, into mouse liver. Here we report that expression of this pathway ameliorates many of the metabolic parameters associated with obesity by increasing fatty acid degradation and decreasing total fat mass accumulation.

Since mammals do not normally have the glyoxylate shunt, its effect on lipid metabolism was unknown. We hypothesized that expression could lead to increased or decreased fatty acid degradation based on how the cell adapted to these enzymes. In addition, hepatocytes could also use the pathway for gluconeogenesis, similar to how plants and bacteria use the shunt.
We first tested the effect of glyoxylate shunt expression in HepG2 hepatocytes and found that expression led to increased fatty acid degradation compared to WT cells (Figures 2D, 2E, and 2G). Furthermore, knocking down ME1 abolished the increased fatty acid uptake observed in ACE cells (Figure 2I). These results suggest that hepatocytes adapted to the non-native pathway by creating an alternate cycle through aceA, aceB, and ME1 for complete acetyl-CoA oxidation to CO2 and that the glyoxylate shunt functions differently in hepatocytes than plants and bacteria, where it is used to conserve carbon.

We next investigated the effect of the glyoxylate shunt on whole-body metabolism by tail-vein-injecting vectors containing aceA and aceB into mice. ACE mice gained less weight after 6 weeks on an HFD than lacZ-injected mice (Figures 4C–4E), and this was accompanied with a decrease in fat mass accumulation (Figures 4F–4G). We also found that the majority of the weight difference between ACE and lacZ-injected female mice was due to fat mass (Figure 4F). Female ACE mice accumulated less visceral fat than lacZ-injected mice (Figures 5A and 5B), and this resulted in decreased circulating leptin levels (Figure 5C). These results demonstrate that the glyoxylate shunt effectively alters whole-body lipid metabolism.

Since the glyoxylate shunt exerted such a significant effect on lipid homeostasis, we investigated the intracellular levels of key metabolites to further understand the underlying mechanism of decreased fat storage in ACE mice. We found that ACE mice had decreased levels of plasma triglycerides (Figure 6D), likely a consequence of increased fatty acid oxidation and decreased adipose accumulation. Additionally, ACE mice were found to have decreased plasma cholesterol levels (Figure 6D). Since acetyl-CoA is a precursor for cholesterol biosynthesis, the glyoxylate shunt may decrease cholesterol levels by providing an additional acetyl-CoA-consuming pathway. Alternatively, the glyoxylate shunt may decrease the available TG for VLDL and lead to apoB destabilization, negatively affecting cholesterol plasma concentrations. Although glyoxylate shunt activity relative to other pathways was not assessed, we found that the enzyme activity generated by tail-vein injection was sufficient to perturb whole-body adipose accumulation and plasma lipid concentrations.

Consistent with our hypothesis that the glyoxylate shunt creates an alternate cycle for acetyl-CoA oxidation through the shunt and either PEPCK or ME1 and diverts citrate transport out of the mitochondria, we found that female ACE mice had lower malonyl-CoA levels, a fatty acid β-oxidation inhibitor, on an HFD than lacZ-injected mice (Figure 6A). Individual metabolites have previously been found to regulate whole-body metabolic profiles (An et al., 2004). Decreasing hepatic malonyl-CoA levels by overexpressing malonyl-CoA decarboxylase, a cytosolic enzyme catalyzing the conversion of malonyl-CoA to acetyl-CoA, reverses insulin resistance (An et al., 2004). Here we find that decreasing malonyl-CoA levels via the glyoxylate shunt reduces whole-body adiposity. Total liver ATP levels were also markedly lower in ACE mice (Figure 6B). This may be attributed to the shunt bypassing the oxidative portion of the TCA cycle and the possibility that the NADH produced by cytosolic malate dehydrogenase (Figure 1) was oxidized in producing lactate rather than shuttling back into mitochondria. However, other unknown mechanisms may exist for decreasing the cell’s capacity for oxidative phosphorylation. This decrease
in ATP may explain the observed AMPK activation in ACE cells (Figure 3A). Activated AMPK responds to low energy states by activating ATP producing pathways and inhibiting energy consuming pathways such as fatty acid biosynthesis (Long and Zierath, 2006). This suggests that despite increased fatty acid oxidation, ACE cells generate less energy per fatty acid oxidized than WT. This energy dissipation is similar to the mechanism by which uncoupling proteins regulate the whole-body energy balance. Uncoupling proteins decrease metabolic efficiency by dissipating the proton gradient in the mitochondria, causing energy created from metabolism to be released as heat. Mice overexpressing UCP in skeletal tissue resist diet-induced obesity (Li et al., 2000) and have improved insulin sensitivity. Moreover, liver-specific UCP1 expression leads to increased energy expenditure and decreased liver triglyceride content (Ishigaki et al., 2005). So, similar to uncoupling proteins, the glyoxylate shunt may alter the energy state of the cell in part by decreasing the energy produced from fatty acid oxidation.

To further characterize the female ACE phenotype, we assessed energy expenditure and whole-body substrate oxidation using metabolic cages. Although ACE mice gained less weight over the course of 6 weeks on an HFD, we found no difference in food intake between ACE and lacZ-injected mice (Figure 7A). Instead, we found ACE mice had a decreased RER compared to lacZ-injected mice (Figure 7B), indicative of increased fatty acid oxidation. This shows that ACE mice gain less weight on an HFD because of increased fat oxidation and not because of energy intake. This also demonstrates that the glyoxylate exerts its effect on whole-body metabolism peripherally and not through modulation of satiety sensations. ACE mice had increased energy expenditure during the total 24 hr and light period (Figure 7C) of analysis, indicating that ACE mice weigh less than lacZ-injected mice, despite similar food intake, in part because of increased energy expenditure.

Multiple mouse models exhibiting resistance to diet-induced obesity have been documented (Abu-Elheiga et al., 2003; Elcehly et al., 1999; Li et al., 2000; Phan et al., 2004; Vergnes et al., 2006; Zigman et al., 2005; Ziouzenkova et al., 2007). Here we demonstrate such a model generated by expression of the glyoxylate shunt from E. coli. Mice expressing this pathway had decreased liver malonyl-CoA and ATP levels and a significant decrease in percentage body fat. Bacteria and plants use the glyoxylate shunt to conserve carbon by bypassing the decarboxylation steps of the TCA cycle, allowing glucose production from fatty acids. In contrast, we found the shunt functioned differently in mammals by increasing fatty acid oxidation. This work suggests that using non-native metabolic pathways to understand and explore mammalian metabolism may be a useful approach. Finally, since ACE mice only partially resist diet-induced obesity, our model may have advantages for studying nonsevere forms of obesity.

**EXPERIMENTAL PROCEDURES**

Additional method details can be found in the Supplemental Data.

**Plasmid Construction**

Isocitrate lyase (aceA) and malate synthase (aceB) were cloned from E. coli genomic DNA and fused with a mitochondria leader sequence. Genes were cloned into pBudCE4.1 (Invitrogen) (designated pBudaceAB) and stably transfected into human hepatoma cell line HepG2. Genes aceA and aceB were cloned separately from pBudaceAB into pLIVE vector (Mirus Bio; Madison, WI).

**Cell Culture**

Human hepatoma cell line, HepG2 (American Type Culture Collection) was maintained in DMEM supplemented with 10% heat-inactivated FBS and 50 μg/mL penicillin, 50 μg/mL streptomycin, and 100 μg/mL neomycin at 37°C in a humidified atmosphere containing 5% CO2. Cells were transfected in 60 mm plates with pBudaceAB or pBudCE4.1 with Lipofectamine 2000 (Invitrogen; Carlsbad, CA) according to manufacturer’s protocols. Colonies were selected with DMEM supplemented with 320 μg/mL Zeocin (Invitrogen; Carlsbad, CA). Enzyme assays were performed as described elsewhere (Chelli et al., 1978; Sundaram et al., 1980).

**Metabolite Analysis**

Metabolites were quantified using high-performance liquid chromatography (HPLC) on an Agilent 1100 model (Agilent Technologies; Palo Alto, CA) consisting of a binary pump, autosampler, and degasser connected to an organic acid Aminex HPX-87H column (300 x 7.8 mm, Bio-Rad). Glucose was converted to pentacetate derivative for GC-MS analysis (Tseng and Kalhan, 1983). Fatty acid uptake assays were performed as previously documented (Liao et al., 2005). Production of 14CO2 was measured as previously described (Harwood et al., 2003) using [U-14C] palmitate. Plasma metabolite concentrations were determined as described elsewhere (Castellani et al., 2008), Liver TG content was measured using a triglyceride determination kit (Wako Diagnostics; Richmond, VA). Malonyl-CoA was measured using [1-14C] acetyl CoA and purified fatty acid synthase according to the method of McGarry (McGarry et al., 1978). ATP measurement using a bioluminescence-based assay has been described elsewhere (Evans et al., 2008). 3-hydroxybutyrate was measured using an Autokit 3-HB (Wako Diagnostics; Richmond, VA).

**siRNA ME1 Knockdown**

Malic enzyme 1 (ME1) knockdown was performed using a RNAi Human Starter Kit (QiAGEN; Valencia, CA) by transfecting the following siRNA duplex: r(GAAGTGAUUCAAAAGT(T)). Quantitative RT-PCR was performed using SYBR Green chemistry and Smart Cycler (Cepheid; Sunnyvale, CA) and fold changes were calculated using ΔΔCt method (Livak and Schmittgen, 2001) with GAPDH as an endogenous control. Transfection of a nonsilencing fluorescent siRNA had no effect on phenotype.

**Microarray Analysis**

Our data was submitted to the NCBI Gene Expression Omnibus in MIAME format with access number GSE5903. The data can be accessed at http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=tzqrpeciomgaqzy&acc=GSE5903.

Isolated total RNA samples were processed using HGU-133A_2 arrays as recommended by Affymetrix, Inc. (Affymetrix GeneChip Expression Analysis Technical Manual, Affymetrix, Inc.; Santa Clara, CA). The results were quantified and analyzed using GCOS 1.2 software (Affymetrix, Inc.) using default values. Expression fold changes were calculated using dChip software (Zhong et al., 2003), and results were filtered using a 90% confidence bound of fold change. Expression changes were verified using RT-PCR (Table S5).

**Western Blot**

Western blot was performed using standard techniques. For time-course experiments, ACE and WT cells were given DMEM supplemented with 300 μM palmitate and protein was harvested at various time points over 24 hr. Primary antibody incubation was overnight at 1:1000 dilution at 4°C and secondary antibody incubation was at 1:10,000 dilution for 1 hr at room temperature. Antibodies were from Invitrogen and Cell Signaling (Danvers, MA).

**Animal Experiments**

All animal procedures and care were per an institutional ARC-approved protocol. Male and female C57BL/6 mice (Taconic; Hudson, NY) were housed in cages of 1–4 at 22–24°C with a 12 hr light/dark cycle with food and water provided ad libitum. Genes aceA and aceB were cloned separately from...
pBudaceAB into pLIVE vector (Mirus Bio; Madison, WI) and tail vein injected (Alino et al., 2003; Bates et al., 2006; Huang et al., 2006) when mice were 6–7 weeks of age. At 6–7 weeks of age mice were injected with either ACEAB or lacZ and placed on a low fat chow or high-fat diet.

**Quantitative RT-PCR**

Total RNA was isolated female ACE and lacZ mouse liver after overnight fast using RNeasy-plus columns (QIAGEN; Valencia, CA). First-strand cDNA was synthesized using Superscript III Reverse Transcriptase (Invitrogen; Carlsbad, CA). Quantitative RT-PCR was performed using SYBR Green Chemistry, Quantitect Primer Assays (QIAGEN; Valencia, CA), and Smart Cycler (Cepheid; Sunnyvale, CA), and fold changes were calculated using ΔΔCt method (Livak and Schmittgen, 2001) with β-actin as an endogenous control.

**Fat Pad and Leptin Analysis**

Visceral fat pads from female ACE and lacZ mice were removed and weighed after 6 weeks on an HFD. Blood was drawn after an overnight fast and leptin was measured using ELISA (Crystal Chem; Downers Grove, IL).

**Metabolic Cages**

Animals were housed individually in a series of eight, airtight chambers designed to assess the metabolic activity of mice over three 12 hr light/12 hr dark cycles (Oxymax, Columbus Instruments, Columbus, OH). Animals were acclimated to the chambers over the first 48 hr, and data were collected over the subsequent 24 hr. The mice had free access to water and powdered food presented from a food hopper attached to a scale. The rate of oxygen consumption (VO2) and carbon dioxide production (VCO2) were calculated and averaged over the entire final 24 hr period as well as for the light and dark cycle for each mouse. Energy expenditure (EE) was calculated as previously described (Bohlooly et al., 2005) using the equation EE (Kcal/kg/hr) = (3.815 + 1.232 × RER) × VO2 where VO2 is the volume of oxygen consumed per hour normalized to body weight and RER represents VCO2/VO2.

**SUPPLEMENTAL DATA**

Supplemental data include nine figures, five tables, Supplemental Experimental Procedures, and Supplemental References and can be found with this article online at http://www.cell.com/cell-metabolism/supplemental/S1550-4131(09)00120-X.

Received: January 8, 2009
Revised: March 17, 2009
Accepted: April 23, 2009
Published: June 2, 2009

**REFERENCES**


Mice with Glyoxylate Shunt Resist Diet-Induced Obesity